DE69724761D1 - Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat - Google Patents

Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat

Info

Publication number
DE69724761D1
DE69724761D1 DE69724761T DE69724761T DE69724761D1 DE 69724761 D1 DE69724761 D1 DE 69724761D1 DE 69724761 T DE69724761 T DE 69724761T DE 69724761 T DE69724761 T DE 69724761T DE 69724761 D1 DE69724761 D1 DE 69724761D1
Authority
DE
Germany
Prior art keywords
chelate
toxin
medicine
net charge
biotinylated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69724761T
Other languages
English (en)
Other versions
DE69724761T2 (de
Inventor
A Khawli
L Epstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Techniclone Inc
Original Assignee
Techniclone Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techniclone Inc filed Critical Techniclone Inc
Publication of DE69724761D1 publication Critical patent/DE69724761D1/de
Application granted granted Critical
Publication of DE69724761T2 publication Critical patent/DE69724761T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69724761T 1996-01-11 1997-01-06 Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat Expired - Lifetime DE69724761T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58607596A 1996-01-11 1996-01-11
US586075 1996-01-11
PCT/US1997/000307 WO1997025069A1 (en) 1996-01-11 1997-01-06 Antibodies with reduced net positive charge

Publications (2)

Publication Number Publication Date
DE69724761D1 true DE69724761D1 (de) 2003-10-16
DE69724761T2 DE69724761T2 (de) 2004-08-05

Family

ID=24344206

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69724761T Expired - Lifetime DE69724761T2 (de) 1996-01-11 1997-01-06 Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat

Country Status (10)

Country Link
EP (1) EP0873139B1 (de)
JP (2) JP2000503301A (de)
KR (1) KR100485240B1 (de)
AT (1) ATE249243T1 (de)
AU (1) AU730388B2 (de)
CA (1) CA2242750C (de)
DE (1) DE69724761T2 (de)
ES (1) ES2206683T3 (de)
RU (1) RU2219949C2 (de)
WO (1) WO1997025069A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047903A1 (en) * 2003-11-07 2005-05-26 Upstate Usa. Inc. A method for generating antibody conjugates that preserves antigen recognition
US20150344580A1 (en) * 2012-06-05 2015-12-03 Eldar Kim Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7
CN107973856B (zh) 2012-07-04 2021-11-23 弗·哈夫曼-拉罗切有限公司 共价连接的抗原-抗体缀合物
RU2017128512A (ru) 2012-07-04 2019-02-15 Ф. Хоффманн-Ля Рош Аг Антитела к теофиллину и способы их применения
CN104411725B (zh) * 2012-07-04 2018-09-28 弗·哈夫曼-拉罗切有限公司 抗生物素抗体及使用方法
RU2694981C2 (ru) 2014-01-03 2019-07-18 Ф. Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
EP3089759B1 (de) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Kovalent verknüpfte polypeptidtoxin-antikörperkonjugate
PL3089996T3 (pl) 2014-01-03 2021-12-13 F. Hoffmann-La Roche Ag Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
WO1988007553A1 (en) * 1987-03-26 1988-10-06 Teijin Limited Process for preparing antibody complex
EP0593452A1 (de) * 1989-11-30 1994-04-27 Mallinckrodt Medical, Inc. Verfahren zur herstellung eines mit metallradionuklid markierten proteins
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
SE9100142L (sv) * 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
ATE210464T1 (de) * 1992-06-09 2001-12-15 Neorx Corp BIOTIN-DOTA KONJUGATE UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
JPH0853499A (ja) * 1994-08-10 1996-02-27 Green Cross Corp:The キメラ抗体Ｆａｂ断片のオリゴマー体

Also Published As

Publication number Publication date
WO1997025069A1 (en) 1997-07-17
CA2242750A1 (en) 1997-07-17
JP2000503301A (ja) 2000-03-21
AU730388B2 (en) 2001-03-08
ATE249243T1 (de) 2003-09-15
RU2219949C2 (ru) 2003-12-27
JP2012131808A (ja) 2012-07-12
KR19990077198A (ko) 1999-10-25
EP0873139B1 (de) 2003-09-10
ES2206683T3 (es) 2004-05-16
KR100485240B1 (ko) 2006-10-24
AU1693997A (en) 1997-08-01
CA2242750C (en) 2007-03-27
EP0873139A1 (de) 1998-10-28
DE69724761T2 (de) 2004-08-05

Similar Documents

Publication Publication Date Title
ATE162403T1 (de) Modifizierte antikörper mit kontrollierter clearance-zeit
DE69520739T2 (de) Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats
NO901986D0 (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
EE05212B1 (et) Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i
ES2061730T3 (es) Nuevos anticuerpos.
EP1808155A3 (de) Hybride Antikörperserumproteine
NZ513498A (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
TR200003161T2 (tr) Poliol-IFN-Beta konjugatları
DE69926630D1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
FI950062A (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
NO20010021D0 (no) Trifunksjonelt reagens for konjugering til et biomolekyl
CA2000913A1 (en) Family of high affinity antibodies for cancer treatment
DE69724761D1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
DE69230970D1 (de) Bicylclische, polyazamakrocyclocarbonsäure-komplexe, konjugate, herstellung und verwendung als kontraststoffe
DK0570575T3 (da) Bicykloazamakrocyklophosphonsyre, komplekser, konjugater, kontrastmidler og fremstilling heraf
Bacha et al. Anti‐arthritic effects demonstrated by an interleukin‐2 receptor‐targeted cytotoxin (DAB486IL‐2) in rat adjuvant arthritis
RU98115277A (ru) Антитела с уменьшенным суммарным положительным зарядом
NO954442L (no) Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler, og fremgangsmåter for deres fremstilling
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
BR9913429A (pt) Anticorpos bifuncionais e seu uso na objetivação de agentes antitumor
RU93053897A (ru) Комплексы бициклополиазамакроциклокарбоновых кислот, их конъюгаты, фармацевтическая композиция, способ диагностики, набор и способ получения
Harapanhalli et al. Lysine-directed conjugation of ethidium homodimer to B72. 3 mAb: retention of immunoreactivity and altered tumor targeting
Sveshnikov et al. Respecrins—A new generation of immunotoxins

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition